stockrowPTC Therapeutics, Inc.
PTCT Healthcare Biotechnology
PTC Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.7 billion, up 114.5% from fiscal 2024.
- Revenue
- +69.6%
- EPS
- −410.0%
- Free cash flow
- +90.3%
- Total debt
- +19.3%
Quarter to September 2026, against a year earlier
Follow PTCT
Alert me
PTC Therapeutics, Inc. (PTCT) EBITDA
PTC Therapeutics, Inc.'s EBITDA for fiscal 2025 was $888.9M, compared with −$78.7M in fiscal 2024. Over the twelve months to 30 September 2026 it was $191.8M. Over the past ten years it has ranged from −$345.5M (fiscal 2020) to $888.9M (fiscal 2025) — the current reading is the highest in ten years. PTC Therapeutics, Inc. ranks 21st of 594 Biotechnology companies by EBITDA.
EBITDA, annual
Embed this chart
Annual newest first
| Period | EBITDA | Change |
|---|---|---|
| FY2025 | $888.9M | — |
| FY2024 | −$78.7M | — |
| FY2023 | $14.6M | — |
| FY2022 | −$281.6M | — |
| FY2021 | −$303.2M | — |
| FY2020 | −$345.5M | — |
| FY2019 | −$210.2M | — |
| FY2018 | −$89.5M | — |
| FY2017 | −$45.6M | — |
| FY2016 | −$126.6M | — |
Quarterly newest first
| Period | EBITDA | Change |
|---|---|---|
| Sep 2026 | $37.4M | (76.67%) |
| Jun 2026 | $160.2M | 178.57% |
| Mar 2026 | $57.5M | — |
| Dec 2025 | −$63.2M | — |
| 43 more quarters | Free account |
Against its own ten years
EBITDA against peers
| Company | EBITDA |
|---|---|
| PTCT PTC Therapeutics, Inc. | $191.8M |
| MANE Veradermics Incorporated compare | −$88.4M |
| BLTE Belite Bio, Inc. Sponsored ADR compare | −$118.6M |
| KOD Kodiak Sciences Inc. compare | −$220.8M |
| CGON CG Oncology, Inc. compare | −$250.7M |
| COGT Cogent Biosciences, Inc. compare | −$388.7M |
| SRRK Scholar Rock Holding Corporation compare | −$405.8M |
| IMVT Immunovant, Inc. compare | −$565.6M |
| MIRM Mirum Pharmaceuticals, Inc. compare | −$867.1M |
What EBITDA is
EBITDA shows what a company earns from its operations before interest, taxes and the non-cash charges for depreciation and amortization.
Reported line item
More on PTCT
- Revenue
- Net income
- EPS (diluted)
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement